Application of Bispecific T Cells Engagers in Hematological Malignancy

Abstract

Over the past decade, it has played a significant role in immunology and is commonly used to combat malignant blood tumors. The product that has been invented and is the most successful one is blinatumomab. BiTEs are dual-specificity T-cell engagers composed of two linked antigen-binding variable fragments, and these fragments do not contain the constant domains of their parent antibodies. This makes it a project with great development potential. Indeed, BiTEs still face many challenges, including short half-life, tumor microenvironment (TME), cytokine release syndrome (CRS), and neurotoxicity. For these side effects resulting from the treatments, BiTEs are still in a stage of research and overcoming. Modern medicine is urgently seeking effective and safe methods for treating cancer. Since the advent of BiTEs, a large number of applications have been made to develop the increasing maturity of blinatumomab, which has also led to the wider application of BiTEs. A large number of clinical trials have confirmed that BiTEs have a high rate of targeted therapy for malignant hematological tumors.